Press Releases
Nov 16, 2022

Astellas' SPOTLIGHT trial meets primary endpoint of progression-free survival (PFS) Full data to be presented at future scientific congress TOKYO, Nov. 17, 2022 /PRNewswire/ -- Astellas Pharma...

Oct 24, 2022

- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's novel product candidates for rare monogenic

Oct 11, 2022

SKYLIGHT 4™ study results demonstrate the 52-week safety and tolerability of fezolinetant 30 mg and 45 mg once daily Pooled analyses will also be presented from SKYLIGHT 1™ and SKYLIGHT 2™...

EXPLORE ALL US PRESS RELEASES

Articles
Sep 20, 2022

Astellas was recently ranked in Seramount’s 2022 list of 100 Best Companies and Best Companies for Dads highlighting our commitment to creating a workplace where working parents are valued and...

Sep 20, 2022

Astellas ranked again in Seramount’s 2022 “100 Best Companies” list and Best Companies for Dads

Sep 13, 2022

C3 Prize Winner Shares How Her Father’s Experience with Cancer Inspired Her to Create New Patient App Astellas Pharma senior vice president and global head of Patient Centricity Dr. Anthony...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products